<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257257</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5825</org_study_id>
    <nct_id>NCT00257257</nct_id>
  </id_info>
  <brief_title>Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients</brief_title>
  <acronym>SERENADE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-na√Øve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary: Effect on HbA1c over 6 months in drug-naive patients with type 2 diabetes&#xD;
&#xD;
      Secondary: Effect on glucose, insulin, C-peptide, insulin resistance, body weight,&#xD;
      HDL-cholesterol, triglycerides, blood pressure - Safety, tolerability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study will be up to 6 and 1/2 months including screening period (up&#xD;
      to 14 days) and double-blind treatment period (approximately 6 months) in patients on mild&#xD;
      hypocaloric diet (600 kcal/day deficit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in HbA1C from baseline to Month 6.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, fasting insulin, C-peptide, HOMA analysis, body weight, HDL-cholesterol, triglycerides, blood pressure, safety (physical examination, vital signs, laboratory tests, adverse events).</measure>
  </secondary_outcome>
  <enrollment type="Actual">281</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant (SR141716)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged greater than or equal to 18 years.&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes as defined by WHO criteria for at least 2 months but no&#xD;
             longer than 3 years.&#xD;
&#xD;
          -  Type 2 diabetes not previously treated by a pharmacological agent.&#xD;
&#xD;
        Note:&#xD;
&#xD;
          -  a) insulin use is accepted if it is not within 6 months prior to screening visit and&#xD;
             only for the following reasons:&#xD;
&#xD;
               -  prior use for management of gestational diabetes,&#xD;
&#xD;
               -  short-term (less than or equal to 1 month) use to maintain glycemic control for&#xD;
                  hospitalization, medical procedures, or intervention.&#xD;
&#xD;
          -  b) use of an oral antidiabetic agent is accepted if it is not within 6 months prior to&#xD;
             screening visit and only if it was prescribed for no more than 4 months.&#xD;
&#xD;
          -  HbA1C greater than or equal to 7% and less than or equal to 10%.&#xD;
&#xD;
          -  Having signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Weight loss &gt; 5 kg within 3 months prior to screening visit.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Absence of medically approved contraceptive methods for females of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Marijuana or hashish users.&#xD;
&#xD;
          -  Administration of other investigational drugs within 30 days prior to screening visit.&#xD;
&#xD;
          -  Previous participation in a rimonabant study.&#xD;
&#xD;
          -  Presence or history of allergic reaction or intolerance to multiple drugs.&#xD;
&#xD;
          -  Presence of any other condition (e.g., geographic, social) that the Investigator feels&#xD;
             that would restrict or limit the patient's participation for the duration of the&#xD;
             study.&#xD;
&#xD;
        Related to endocrine and metabolic disorders:&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the&#xD;
             Investigator.&#xD;
&#xD;
        Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine&#xD;
        is stable for at least 3 months prior to screening visit.&#xD;
&#xD;
          -  Fasting C-peptide &lt; 1.0 ng/mL.&#xD;
&#xD;
        Related to other disorders:&#xD;
&#xD;
          -  Presence of any severe medical or psychological condition that in the opinion of the&#xD;
             Investigator would compromise the patient's safety or successful participation in the&#xD;
             study.&#xD;
&#xD;
          -  Presence or history of cancer within the past five years with the exception of&#xD;
             adequately treated localized basal cell skin cancer or in situ uterine cervical&#xD;
             cancer.&#xD;
&#xD;
        Related to laboratory findings:&#xD;
&#xD;
          -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.&#xD;
&#xD;
          -  Abnormal TSH level (TSH &gt; ULN or &lt; LLN).&#xD;
&#xD;
          -  Hemoglobin &lt; 11 g/dL and/or neutrophils &lt; 1,500/mm3 and/or platelets &lt; 100,000/mm3.&#xD;
&#xD;
          -  Positive urine pregnancy test.&#xD;
&#xD;
          -  Positive urine test for marijuana or hashish metabolites.&#xD;
&#xD;
        Related to previous or concomitant medications:&#xD;
&#xD;
          -  Oral antidiabetic agent except if it is not within 6 months prior to screening visit&#xD;
             and only if it was prescribed for no more than 4 months.&#xD;
&#xD;
          -  Insulin except if it is not within 6 months prior to screening visit and only for&#xD;
             management of gestational diabetes or short-term use to maintain glycemic control for&#xD;
             hospitalization, medical procedures, or intervention.&#xD;
&#xD;
          -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>November 21, 2005</study_first_submitted>
  <study_first_submitted_qc>November 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2005</study_first_posted>
  <last_update_submitted>April 17, 2009</last_update_submitted>
  <last_update_submitted_qc>April 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

